Reimbursement and Practice Policies among Providers of Buprenorphine-Naloxone Treatment

Abstract

Background: Physician acceptance of cash payment and low adherence to practice guidelines may contribute to buprenorphine-naloxone diversion. The purpose of this study was to investigate the clinical practice policies of physicians who provide office-based treatment for opioid dependence with buprenorphine-naloxone. Methods: Data were obtained from 31 of 71 practices surveyed (response rate 43.7%) that provided answers to at least some of the survey questions. Results: Of these practices, 28 (90.3%) accepted cash as payment and 6 (19.4%) accepted only cash for treatment services. Analysis of open-ended responses to questions about office policies revealed wide variation among practices and overall suboptimal adherence to recommended treatment guidelines. Conclusions: These results underscore the need for continuing education for physicians who prescribe buprenorphine-naloxone.

Keywords

Buprenorphine opioid-related disorders physician practice patterns

Get full access to this article

View all access options for this article.

References

Ponizovsky

A M

, Margolis

, Heled

, Rosca

, Radomislensky

and Grinshpoon

. 2010. Improved quality of life, clinical, and psychosocial outcomes among heroin-dependent patients on ambulatory buprenorphine maintenance. Subst Use Misuse., 45: 288–313.

Parran

T V

, Adelman

C A

Merkin

. 2010. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend, 106: 56–60.

Monte

A A

, Mandell

, Wilford

B B

, Tennyson

and Boyer

E W

. 2009. Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. J Addict Dis, 28: 226–231.

Schuman-Olivier

, Albanese

Nelson

S E

. 2010. Self-treatment: illicit buprenorphine use by opioid dependent treatment seekers. J Subst Abuse Treat, 39: 41–50.

Center for Substance Abuse Treatment. 2004. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40, Rockville, MD: Substance Abuse and Mental Health Services Administration. DHHS Publication No. (SMA) 04-3939

Horgan

C M

, Reif

, Hodgkin

, Garnick

D W

and Merrick

E L

. 2008. Availability of addiction medications in private health plans. J Subst Abuse Treat., 34: 147–156.

Substance Abuse and Mental Health Services Administration. Buprenorphine physician and treatment program locator. Available at: http://buprenorphine.samhsa.gov/bwns_locator/. Accessed April 26, 2011

Reckitt Benckiser Pharmaceuticals. Here to Help Program. Available at: http://www.heretohelpprogram.com/. Accessed April 27, 2011

Magura

, Lee

S J

Salsitz

E A

. 2007. Outcomes of buprenorphine maintenance in office-based practices. J Addict Dis., 26: 13–23.

10.

Colameco

, Armando

and Trotz

. 2005. Opiate dependence treatment with buprenorphine: one year's experience in a Family Practice residency setting. J Addict Dis., 24: 25–32.

11.

Walley

A Y

, Alperen

J K

Cheng

D M

. 2008. Office-based management of opioid dependence with buprenorphine: clinical practice and barriers. J Gen Intern Med., 23: 1393–1398.

12.

Thomas

C P

, Reif

, Haq

, Wallack

S S

, Hoyt

and Ritter

G A

. 2008. Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists. Psychiatr Serv., 59: 909–916.